Published in Vaccine Weekly, February 18th, 2004
The first, U.S. patent number 6,578,558, entitled "Method and apparatus for reducing electroporation-mediated muscle reaction and pain response," includes claims to use less severe methods for delivering an agent, such as a drug or polynucleotide, into a cell. This patent enhances the intellectual property for the oncology, gene therapy, and DNA vaccine applications of electroporation therapy (EPT).
The second patent, U.S. patent number 6,678,566, entitled "Electrical field therapy with reduced histopathological change in muscle," includes claims to methods for reducing changes...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly